increase of 91.1%from RMB38.6 million for the same period in 2010. Net margin, representing net income divided by total revenue, was 13.5% for the second quarter of 2011, compared to 7.1% for the second quarter of 2010. For the first six months of 2011, net income was RMB101.6 million (US$15.7 million), which represented an increase of 72.1% from RMB59.0 million for the same period in 2010. Net margin for the first six months of 2011 was 9.9% as compared to 5.9% for the same period in 2010.
Basic and diluted earnings per American Depository Share ("ADS")for the second quarter of 2011 were RMB1.38 (US$0.21) and RMB1.33 (US$0.21), respectively. Basic and diluted earnings per ADS for the first six months of 2011 were RMB1.90 (US$0.29) and RMB1.84 (US$0.28) respectively. One ADS represents two ordinary shares of the Company.
As of June 30, 2011, the Company had cash, cash equivalents and restricted cash of RMB230.5 million (US$35.6 million), compared to RMB278.7 million as of December 31, 2010.
Financial InformationThe preliminary unaudited condensed consolidated statements of income and balance sheets accompanying this press release have been prepared by management using U.S. GAAP. This preliminary financial information is not intended to fully comply with U.S. GAAP because it does not present all of the financial information and disclosures required by U.S. GAAP.
Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine technology :1
|SOURCE Simcere Pharmaceutical Group|
Copyright©2010 PR Newswire.
All rights reserved
. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study2
. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals3
. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.4
. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production5
. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen6
. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China7
. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 20108
. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study9
. Simceres Diosmectite API Passes EU-GMP Inspection10
. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results11
. Simcere Pharmaceutical Group Files Annual Report on Form 20-F